168 related articles for article (PubMed ID: 31871959)
1. Dosing and Re-Administration of Lentiviral Vector for
Carbonaro-Sarracino DA; Tarantal AF; Lee CCI; Kaufman ML; Wandro S; Jin X; Martinez M; Clark DN; Chun K; Koziol C; Hardee CL; Wang X; Kohn DB
Mol Ther Methods Clin Dev; 2020 Mar; 16():78-93. PubMed ID: 31871959
[TBL] [Abstract][Full Text] [Related]
2. Effects of vector backbone and pseudotype on lentiviral vector-mediated gene transfer: studies in infant ADA-deficient mice and rhesus monkeys.
Carbonaro Sarracino D; Tarantal AF; Lee CC; Martinez M; Jin X; Wang X; Hardee CL; Geiger S; Kahl CA; Kohn DB
Mol Ther; 2014 Oct; 22(10):1803-16. PubMed ID: 24925206
[TBL] [Abstract][Full Text] [Related]
3. Gene delivery using AAV8
Carbonaro-Sarracino DA; Chun K; Clark DN; Kaufman ML; Jin X; Wang X; Kohn DB
Mol Ther Methods Clin Dev; 2021 Mar; 20():765-778. PubMed ID: 33738330
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects.
Mortellaro A; Hernandez RJ; Guerrini MM; Carlucci F; Tabucchi A; Ponzoni M; Sanvito F; Doglioni C; Di Serio C; Biasco L; Follenzi A; Naldini L; Bordignon C; Roncarolo MG; Aiuti A
Blood; 2006 Nov; 108(9):2979-88. PubMed ID: 16835374
[TBL] [Abstract][Full Text] [Related]
5. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.
Carbonaro DA; Zhang L; Jin X; Montiel-Equihua C; Geiger S; Carmo M; Cooper A; Fairbanks L; Kaufman ML; Sebire NJ; Hollis RP; Blundell MP; Senadheera S; Fu PY; Sahaghian A; Chan RY; Wang X; Cornetta K; Thrasher AJ; Kohn DB; Gaspar HB
Mol Ther; 2014 Mar; 22(3):607-622. PubMed ID: 24256635
[TBL] [Abstract][Full Text] [Related]
6. In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency.
Carbonaro DA; Jin X; Petersen D; Wang X; Dorey F; Kil KS; Aldrich M; Blackburn MR; Kellems RE; Kohn DB
Mol Ther; 2006 Jun; 13(6):1110-20. PubMed ID: 16651028
[TBL] [Abstract][Full Text] [Related]
7. Baboon envelope pseudotyped lentiviral vectors efficiently transduce human B cells and allow active factor IX B cell secretion in vivo in NOD/SCIDγc
Levy C; Fusil F; Amirache F; Costa C; Girard-Gagnepain A; Negre D; Bernadin O; Garaulet G; Rodriguez A; Nair N; Vandendriessche T; Chuah M; Cosset FL; Verhoeyen E
J Thromb Haemost; 2016 Dec; 14(12):2478-2492. PubMed ID: 27685947
[TBL] [Abstract][Full Text] [Related]
8. Long-term in vivo expression of the MFG-ADA retroviral vector in rhesus monkeys transplanted with transduced bone marrow cells.
Kaptein LC; Van Beusechem VW; Rivière I; Mulligan RC; Valerio D
Hum Gene Ther; 1997 Sep; 8(13):1605-10. PubMed ID: 9322093
[TBL] [Abstract][Full Text] [Related]
9. Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression.
Kimura T; Koya RC; Anselmi L; Sternini C; Wang HJ; Comin-Anduix B; Prins RM; Faure-Kumar E; Rozengurt N; Cui Y; Kasahara N; Stripecke R
Mol Ther; 2007 Jul; 15(7):1390-9. PubMed ID: 17505480
[TBL] [Abstract][Full Text] [Related]
10. Rhesus monkey model for fetal gene transfer: studies with retroviral- based vector systems.
Tarantal AF; O'Rourke JP; Case SS; Newbound GC; Li J; Lee CI; Baskin CR; Kohn DB; Bunnell BA
Mol Ther; 2001 Feb; 3(2):128-38. PubMed ID: 11237669
[TBL] [Abstract][Full Text] [Related]
11. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
Silver JN; Elder M; Conlon T; Cruz P; Wright AJ; Srivastava A; Flotte TR
Hum Gene Ther; 2011 Aug; 22(8):935-49. PubMed ID: 21142972
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction.
Carbonaro DA; Jin X; Wang X; Yu XJ; Rozengurt N; Kaufman ML; Wang X; Gjertson D; Zhou Y; Blackburn MR; Kohn DB
Blood; 2012 Nov; 120(18):3677-87. PubMed ID: 22833548
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow gene therapy for adenosine deaminase deficiency.
Kaptein LC; Einerhand MP; Braakman E; Valerio D; van Beusechem VW
Immunodeficiency; 1993; 4(1-4):335-45. PubMed ID: 7909479
[TBL] [Abstract][Full Text] [Related]
14. PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum.
Croyle MA; Callahan SM; Auricchio A; Schumer G; Linse KD; Wilson JM; Brunner LJ; Kobinger GP
J Virol; 2004 Jan; 78(2):912-21. PubMed ID: 14694122
[TBL] [Abstract][Full Text] [Related]
15. Use of Heterologous Vesiculovirus G Proteins Circumvents the Humoral Anti-envelope Immunity in Lentivector-Based In Vivo Gene Delivery.
Munis AM; Mattiuzzo G; Bentley EM; Collins MK; Eyles JE; Takeuchi Y
Mol Ther Nucleic Acids; 2019 Sep; 17():126-137. PubMed ID: 31254925
[TBL] [Abstract][Full Text] [Related]
16. HIV-1-derived lentiviral vectors and fetal route of administration on transgene biodistribution and expression in rhesus monkeys.
Jimenez DF; Lee CI; O'Shea CE; Kohn DB; Tarantal AF
Gene Ther; 2005 May; 12(10):821-30. PubMed ID: 15815706
[TBL] [Abstract][Full Text] [Related]
17. Expression of human adenosine deaminase in mice after transplantation of genetically-modified bone marrow.
Kaleko M; Garcia JV; Osborne WR; Miller AD
Blood; 1990 Apr; 75(8):1733-41. PubMed ID: 2328323
[TBL] [Abstract][Full Text] [Related]
18. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.
Publicover J; Ramsburg E; Rose JK
J Virol; 2005 Nov; 79(21):13231-8. PubMed ID: 16227246
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.
Candotti F; Shaw KL; Muul L; Carbonaro D; Sokolic R; Choi C; Schurman SH; Garabedian E; Kesserwan C; Jagadeesh GJ; Fu PY; Gschweng E; Cooper A; Tisdale JF; Weinberg KI; Crooks GM; Kapoor N; Shah A; Abdel-Azim H; Yu XJ; Smogorzewska M; Wayne AS; Rosenblatt HM; Davis CM; Hanson C; Rishi RG; Wang X; Gjertson D; Yang OO; Balamurugan A; Bauer G; Ireland JA; Engel BC; Podsakoff GM; Hershfield MS; Blaese RM; Parkman R; Kohn DB
Blood; 2012 Nov; 120(18):3635-46. PubMed ID: 22968453
[TBL] [Abstract][Full Text] [Related]
20. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
